Rare diseases: Opportunistic or Philanthropic?
This article was originally published in Scrip
With special incentives associated with orphan drug status and the technological advances underpinned by better understanding of the underlying genetics, it is not surprising that rare diseases have become an increasingly attractive target for the pharma and biotech companies. However, while most companies' entry into the orphan drug field has been primarily motivated by the potential for technology breakthroughs and the business opportunity, the societal impact is also a potential major driver.
You may also be interested in...
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.